New Key Statistics Module, Z-Score and F-Score
NAS:DAWN Key Ratios
| Market Cap $ M | 2,224.78 |
| Enterprise Value $ M | 1,786.46 |
| P/E(ttm) | -- |
| PE Ratio without NRI | -- |
| Forward PE Ratio | -- |
| Price/Book | 5.03 |
| Price/Sales | 14.06 |
| Price/Free Cash Flow | -- |
| Price/Owner Earnings | -- |
| Payout Ratio % | -- |
| Revenue (TTM) $ M | 158.00 |
| EPS (TTM) $ | -1.04 |
| Beneish M-Score | -1.78 |
| 10-y EBITDA Growth Rate % | -- |
| 5-y EBITDA Growth Rate % | -22.80 |
| y-y EBITDA Growth Rate % | -- |
| EV-to-EBIT | -13.98 |
| EV-to-EBITDA | -14.41 |
| PEG | -- |
| Shares Outstanding M | 103.33 |
| Net Margin (%) | -67.85 |
| Operating Margin % | -80.76 |
| Pre-tax Margin (%) | -69.10 |
| Quick Ratio | 7.91 |
| Current Ratio | 8.02 |
| ROA % (ttm) | -20.19 |
| ROE % (ttm) | -22.98 |
| ROIC % (ttm) | -455.40 |
| Dividend Yield % | -- |
| Altman Z-Score | 18.80 |
DAWN Number of Guru Trades
DAWN Volume of Guru Trades
Gurus Latest Trades with NAS:DAWN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
NAS:DAWN is held by these investors
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Day One Biopharmaceuticals Inc Insider Transactions
No Available Data
Guru Commentaries on NAS:DAWN
2025 Q1
What the manager wrote
Day One Biopharmaceuticals Inc. develops and commercializes targeted therapies for patients with genetically defined cancers. Their lead drug Ojemda is used to treat certain types of brain tumors (gliomas) in patients six months and older. The launch has been promising with 280 patients on therapy in December. Despite its early success, there are concerns about the addressable market and prescribing patterns. We decided to sell out of the position, which declined by -35% for the time it was held in the quarter.
News about NAS:DAWN
Total 0- 1
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers